Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Richard Pulik	Chief Financial Officer Show All	Sale to Issuer (Sale to Issuer)	-1.2K	-0.000177%	-0.6%	197.6K	20.3 - 20.3	-25.0K	25 Nov 2025	20 Nov 2025 - 20 Nov 2025
Eric Venker	President & CEO of Immunovant Show All	Sale to Issuer (Sale to Issuer)	-7.1K	-0.001013%	-0.6%	1.2M	20.3 - 20.3	-142.9K	25 Nov 2025	20 Nov 2025 - 20 Nov 2025
	—	Open Market Disposition (Open Market Disposition)	-1.3M	-0.186918%	-4.4%	28.1M	20.2 - 20.3	-26.3M	22 Nov 2025	19 Nov 2025 - 19 Nov 2025
Vivek Ramaswamy	Founder & Former Chairman Show All	Open Market Disposition (Open Market Disposition)	-1.9M	-0.26666%	-3.8%	47.0M	20.3 - 20.8	-37.9M	17 Nov 2025	13 Nov 2025 - 17 Nov 2025
Eric Venker	President & CEO of Immunovant Show All	Derivative Exercise and Sale (Derivative Exercise and Sale)	-200.0K	-0.028948%	—	1.2M	3.9 - 20.2	-3.3M	08 Nov 2025	07 Nov 2025 - 07 Nov 2025
Eric Venker
James C. Momtazee
Melissa B. Epperly
Ilan Oren
Ilan Oren
James C. Momtazee
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Richard Pulik
Eric Venker
Richard Pulik
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker
Eric Venker